BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab. BeyondSpring Inc. was founded in 2010 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone1-646-305-6387
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees38
OptionableNot Optionable
Beyondspring (NASDAQ:BYSI) Frequently Asked Questions
What is Beyondspring's stock symbol?
Beyondspring trades on the NASDAQ under the ticker symbol "BYSI."
How were Beyondspring's earnings last quarter?
Beyondspring Inc (NASDAQ:BYSI) released its quarterly earnings data on Tuesday, October, 23rd. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.62) by $0.08. View Beyondspring's Earnings History.
When is Beyondspring's next earnings date?
What price target have analysts set for BYSI?
2 brokerages have issued 1-year price targets for Beyondspring's stock. Their predictions range from $35.00 to $60.00. On average, they expect Beyondspring's stock price to reach $47.50 in the next twelve months. This suggests a possible upside of 163.7% from the stock's current price. View Analyst Price Targets for Beyondspring.
What is the consensus analysts' recommendation for Beyondspring?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beyondspring in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Beyondspring.
What are Wall Street analysts saying about Beyondspring stock?
Here are some recent quotes from research analysts about Beyondspring stock:
- 1. According to Zacks Investment Research, "BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. " (12/25/2018)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $60 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, Plinabulin. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile." (12/6/2018)
- 3. Maxim Group analysts commented, "BeyondSpring reported 3Q18 (on 10/23) with expenses of $12.4M. The company ended the period with a cash balance of $22.4M. The company has runway into early 2019 though we expect BYSI needs to raise capital. Combined with the recent pullback in valuation, driven in part by macro factors such as contracting multiples in the healthcare space, we lower our price target to $35, from $48 – still plenty of upside." (10/25/2018)
Has Beyondspring been receiving favorable news coverage?
News stories about BYSI stock have trended somewhat positive recently, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Beyondspring earned a news impact score of 1.3 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
Who are some of Beyondspring's key competitors?
Some companies that are related to Beyondspring include Myovant Sciences (MYOV), Theravance Biopharma (TBPH), Innoviva (INVA), Prestige Consumer Healthcare (PBH), Allakos (ALLK), Aimmune Therapeutics (AIMT), Nabriva Therapeutics (NBRV), Clovis Oncology (CLVS), Uniqure (QURE), TherapeuticsMD (TXMD), Corcept Therapeutics (CORT), Spectrum Pharmaceuticals (SPPI), Cambrex (CBM), Esperion Therapeutics (ESPR) and Phibro Animal Health (PAHC).
Who are Beyondspring's key executives?
Beyondspring's management team includes the folowing people:
- Dr. Lan Huang, Co-Founder, Chairman & CEO (Age 48)
- Mr. Dongheng Liu, Chief Financial Officer (Age 37)
- Mr. Richard J. Daly, Chief Operating Officer (Age 58)
- Ms. Amy Yang, Controller
- Dr. Ramon W. Mohanlal, Chief Medical Officer of BeyondSpring U.S. (Age 61)
When did Beyondspring IPO?
(BYSI) raised $4 million in an initial public offering on Thursday, March 9th 2017. The company issued 200,000 shares at a price of $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) acted as the underwriter for the IPO.
How do I buy shares of Beyondspring?
Shares of BYSI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Beyondspring's stock price today?
One share of BYSI stock can currently be purchased for approximately $18.01.
How big of a company is Beyondspring?
Beyondspring has a market capitalization of $404.14 million. The company earns $-91,760,000.00 in net income (profit) each year or ($4.40) on an earnings per share basis. Beyondspring employs 38 workers across the globe.
What is Beyondspring's official website?
How can I contact Beyondspring?
Beyondspring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 1-646-305-6387 or via email at [email protected]
MarketBeat Community Rating for Beyondspring (NASDAQ BYSI)
MarketBeat's community ratings are surveys of what our community members think about Beyondspring and other stocks. Vote "Outperform" if you believe BYSI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BYSI will underperform the S&P 500 over the long term. You may vote once every thirty days.
